AstraZeneca gets regulator's nod to market cancer drug in India

AstraZeneca Pharma has secured approval from India's drug regulator for its cancer treatment Trastuzumab Deruxtecan. This drug is now approved for adult patients with unresectable or metastatic HER2-positive solid tumours. It is the first and only antibody drug conjugate in India with a tumour-agnostic indication. This broadens its potential to help more patients with advanced HER2-positive cancers.

from Industry-Economic Times https://ift.tt/wtnoFyL
via IFTTT